Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.38 |
| ▸ | MAP3K12 | Q12852 | 3/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.33 |
| ▸ | AKT1 | P31749 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3880508 | 1.00 | MALT1 (0.38) | MALT1TRPV1MAP3K12GRM2RPS6KB1 | |
| SCHEMBL3879571 | 0.94 | TRPV1 (0.36) | MALT1TRPV1MAP3K12KDM4EALDH1A1 | |
| SCHEMBL3876588 | 0.94 | TRPV1 (0.36) | MALT1TRPV1MAP3K12KDM4EALDH1A1 | |
| SCHEMBL3877679 | 0.93 | MTOR (0.39) | MALT1TRPV1MAP3K12KDM4EHSD17B10 | |
| SCHEMBL3877699 | 0.93 | MTOR (0.39) | MALT1TRPV1MAP3K12KDM4EHSD17B10 | |
| SCHEMBL3884941 | 0.93 | TRPV1 (0.36) | TRPV1MAP3K12RPS6KB1AKT1KDM4E | |
| SCHEMBL3876784 | 0.92 | TRPV1 (0.38) | TRPV1MAP3K12AKT1KDM4EALDH1A1 | |
| SCHEMBL3877691 | 0.91 | MALT1 (0.39) | MALT1TRPV1MAP3K12GRM2 | |
| SCHEMBL3882168 | 0.91 | MALT1 (0.39) | MALT1TRPV1MAP3K12GRM2 | |
| SCHEMBL13761568 | 0.91 | MALT1 (0.39) | MALT1TRPV1MAP3K12GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | GPR174, GPR68, PPARG | MALT1 1393/4885TRPV1 244/4885MAP3K12 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.